EPHB2, His, Cynomolgus
EPHB2, His, Cynomolgus

Immobilized EPHB2, His, Cynomolgus, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-EPHB2 Antibody, hFc Tag with the EC50 of 4.7ng/ml determined by ELISA.

EPHB2, His, Cynomolgus

The purity of EPHB2, His, Cynomolgus is greater than 95% as determined by SEC-HPLC.

EPHB2, His, Cynomolgus

EPHB2, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

EPHB2, His, Cynomolgus

EphB2, a receptor tyrosine kinase for ephrin ligands, is overexpressed in various cancers and plays an important role in tumor progression. EPHB2 promotes endothelial-mesenchymal transition (EMT) and elicits associated pathologic characteristics of glioblastoma multiforme (GBM) such as invasion and migration. EPHB2 is epigenetically overexpressed in hypoxia, a condition highly prevalent in malignancy. Furthermore, HIF-2α is required for EPHB2 stabilization by hypoxia.
Z04785
¥72,752.00

Ask us a question
Product Introduction
Species Cynomolgus
Protein Construction
EPHB2 (Val19-Pro542)
Accession # A0A7N9CQH5		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 59.09 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 65-75 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • EPHB2, His, Cynomolgus
    • EPHB2, His, Cynomolgus

    Immobilized EPHB2, His, Cynomolgus, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-EPHB2 Antibody, hFc Tag with the EC50 of 4.7ng/ml determined by ELISA.

  • EPHB2, His, Cynomolgus
    • EPHB2, His, Cynomolgus

    The purity of EPHB2, His, Cynomolgus is greater than 95% as determined by SEC-HPLC.

  • EPHB2, His, Cynomolgus
    • EPHB2, His, Cynomolgus

    EPHB2, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background EphB2, a receptor tyrosine kinase for ephrin ligands, is overexpressed in various cancers and plays an important role in tumor progression. EPHB2 promotes endothelial-mesenchymal transition (EMT) and elicits associated pathologic characteristics of glioblastoma multiforme (GBM) such as invasion and migration. EPHB2 is epigenetically overexpressed in hypoxia, a condition highly prevalent in malignancy. Furthermore, HIF-2α is required for EPHB2 stabilization by hypoxia.
Synonyms DRT; ERK; HEK5; TYRO5; CAPB; EK5; EPHT3; PCBC; Cek5; EphB2; EPHT3MGC87492; Nuk; Qek2; Sek3

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.